Pharma BD Deal Intelligence
Novartis AG / Endocyte Inc.
2018 · Acquisition/Merger · $2.1B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
94
Worked — the deal delivered on its rationale.
Novartis acquired Endocyte for $2.1B for 177Lu-PSMA-617 radiopharmaceutical candidate.
Key facts
- Announced Oct 18, 2018
- Closed Dec 21, 2018
- Deal value $2.1B
- Deal type Acquisition/Merger
- Therapeutic area Oncology
- Key assets 177Lu-PSMA-617
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals